High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers

Paula Vainio, Laura Lehtinen, Mika Hilvo, T. Mirtti, John Mpindi, Pekka Kohonen, Vidal Fey, Kirsi Ketola, K. Alanen, Merja Perälä, Matej Oresic, Olli Kallioniemi, Kristiina Iljin

    Research output: Contribution to conferenceConference articleScientific

    Original languageEnglish
    Publication statusPublished - 2010
    MoE publication typeNot Eligible
    EventUnravelling Cancer Cell Invasion and Metastasis - Turin, Italy
    Duration: 2 Dec 20103 Dec 2010

    Conference

    ConferenceUnravelling Cancer Cell Invasion and Metastasis
    CountryItaly
    CityTurin
    Period2/12/103/12/10

    Cite this

    Vainio, P., Lehtinen, L., Hilvo, M., Mirtti, T., Mpindi, J., Kohonen, P., Fey, V., Ketola, K., Alanen, K., Perälä, M., Oresic, M., Kallioniemi, O., & Iljin, K. (2010). High-throughput screening for novel prostate cancer drug targets identifies PLA2G7 as a putative target for ERG oncogene positive cancers. Paper presented at Unravelling Cancer Cell Invasion and Metastasis, Turin, Italy.